CtDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

ABSTRACT:

Purpose

Circulating tumor DNA (ctDNA) holds promise as an early endpoint to predict overall survival (OS). The creation and structured interrogation of aggregated datasets inform the hypothesis that ctDNA is reasonably likely to predict treatment benefit. Friends of Cancer Research convened a diverse working group to establish and implement an analysis plan assessing patient-level associations between changes in ctDNA levels with OS and progression-free survival (PFS).

Experimental design

The aggregate dataset included eight clinical trials representing 940 patients with biomarker-positive advanced non-small cell lung cancer treated with tyrosine kinase inhibitors. Detection of baseline and on-treatment ctDNA was assessed for associations with OS and PFS. Additionally, combi

SUBMITTER: Andrews HS 

PROVIDER: S-EPMC12130803 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature